Priavoid

Priavoid GmbH, established in 2017, is a clinical-stage drug development company based in Düsseldorf, Germany. The company focuses on creating disease-modifying treatments for neurodegenerative disorders, including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS).

Priavoid employs a proprietary platform that utilizes mirror-image phage display selection and optimization technologies to develop compounds composed exclusively of D-enantiomeric (mirror image) amino acids. This all-D-peptide development platform enables the generation of lead compounds targeting protein misfolding, particularly in the central nervous system.

The company's pipeline includes several promising candidates:

PRI-002: A drug candidate for Alzheimer's Disease, currently approved by the European Medicines Agency (EMA) for a Phase II clinical trial.

Tau Program: Focused on developing treatments targeting tauopathies, with funding support from the Alzheimer's Association and the Rainwater Charitable Foundation.

Priavoid collaborates with various research institutions and has received funding from notable organizations, including the Alzheimer's Association, the Rainwater Charitable Foundation, and the German Federal Agency for Disruptive Innovation (SPRIND).

Priavoid's mission is to pioneer the development of treatments that dissolve misfolded proteins or oligomers, a challenge previously deemed insurmountable. The company aims to provide hope to patients suffering from serious neurodegenerative diseases by developing highly needed treatments.

Keywords: Priavoid GmbH, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, all-D-peptide development, protein misfolding, PRI-002, tauopathies, clinical-stage drug development, Düsseldorf, Germany.